<DOC>
	<DOCNO>NCT01894594</DOCNO>
	<brief_summary>The objective study assess effect alkali administration bicarbonate potassium level patient Sickle Cell Disease ( SCD ) depress serum bicarbonate level . The study prospective non-blinded evaluation tolerability efficacy alkali repletion 4 week observation two sequential 4 week course escalate oral sodium bicarbonate treatment .</brief_summary>
	<brief_title>Efficacy , Safety Study Benefit Alkali Therapy Sickle Cell Disease</brief_title>
	<detailed_description>Primary Objective : To assess effect alkali administration bicarbonate potassium level patient SCD depress serum bicarbonate level . Secondary Objectives : To assess effect alkali administration improvement hemolysis sequela impair kidney function , ie , LDH , Hgb , reticulocyte count , red cell half-life , muscle strength , Vitamin D level , marker bone turnover , respectively . To assess influence alkali administration marker kidney tubule inflammation . To evaluate intraparenchymal iron patient SCD renal dysfunction . Safety adverse event alkali patient sickle cell disease monitor . This research supplement current knowledge management clinically important subset people SCD renal insufficiency acid-base perturbation .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<criteria>Sickle cell disease patient HbSS eGFR &lt; 90 ml/min/1.73m2 ( determine abbreviate 4 variable modification MDRD equation ) and/or measure urinary albumin creatinine ratio &gt; 30mg/g . Age â‰¥18 year Previous chronic treatment alkali ( include sodium bicarbonate , calcium carbonate bake soda ) Bicarbonate level &gt; 25 mEq/L Decompensated heart failure Uncontrolled systolic blood pressure &gt; 140 mm/Hg ( cutoff systolic hypertension SCD low nonSCD ) Moderatetosevere low extremity edema Projected progression ESRD within 6 month Kidney transplantation Treatment immunosuppressives within last 3 month Vasoocclusive ( VOC ) within 1 week study entry Active ( open ) leg ulcer Change hydroxyurea dose within last 3 month , unless selflimited interruption stable dose Blood transfusion within 8 week , unless chronic transfusion Pregnancy Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Bicarbonate therapy</keyword>
</DOC>